Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells.
Higgins MJ, Beaver JA, Wong HY, Gustin JP, Lauring JD, Garay JP, Konishi H, Mohseni M, Wang GM, Cidado J, Jelovac D, Cosgrove DP, Tamaki A, Abukhdeir AM, Park BH. Higgins MJ, et al. Among authors: cosgrove dp. Cancer Biol Ther. 2011 Feb 1;11(3):358-67. doi: 10.4161/cbt.11.3.14227. Epub 2011 Feb 1. Cancer Biol Ther. 2011. PMID: 21124076 Free PMC article.
Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations.
Lauring J, Cosgrove DP, Fontana S, Gustin JP, Konishi H, Abukhdeir AM, Garay JP, Mohseni M, Wang GM, Higgins MJ, Gorkin D, Reis M, Vogelstein B, Polyak K, Cowherd M, Buckhaults PJ, Park BH. Lauring J, et al. Among authors: cosgrove dp. Oncogene. 2010 Apr 22;29(16):2337-45. doi: 10.1038/onc.2009.516. Epub 2010 Jan 25. Oncogene. 2010. PMID: 20101210 Free PMC article.
Knockin of mutant PIK3CA activates multiple oncogenic pathways.
Gustin JP, Karakas B, Weiss MB, Abukhdeir AM, Lauring J, Garay JP, Cosgrove D, Tamaki A, Konishi H, Konishi Y, Mohseni M, Wang G, Rosen DM, Denmeade SR, Higgins MJ, Vitolo MI, Bachman KE, Park BH. Gustin JP, et al. Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2835-40. doi: 10.1073/pnas.0813351106. Epub 2009 Feb 5. Proc Natl Acad Sci U S A. 2009. PMID: 19196980 Free PMC article.
Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells.
Konishi H, Mohseni M, Tamaki A, Garay JP, Croessmann S, Karnan S, Ota A, Wong HY, Konishi Y, Karakas B, Tahir K, Abukhdeir AM, Gustin JP, Cidado J, Wang GM, Cosgrove D, Cochran R, Jelovac D, Higgins MJ, Arena S, Hawkins L, Lauring J, Gross AL, Heaphy CM, Hosokawa Y, Gabrielson E, Meeker AK, Visvanathan K, Argani P, Bachman KE, Park BH. Konishi H, et al. Proc Natl Acad Sci U S A. 2011 Oct 25;108(43):17773-8. doi: 10.1073/pnas.1110969108. Epub 2011 Oct 10. Proc Natl Acad Sci U S A. 2011. PMID: 21987798 Free PMC article.
The PIK3CA gene as a mutated target for cancer therapy.
Gustin JP, Cosgrove DP, Park BH. Gustin JP, et al. Among authors: cosgrove dp. Curr Cancer Drug Targets. 2008 Dec;8(8):733-40. doi: 10.2174/156800908786733504. Curr Cancer Drug Targets. 2008. PMID: 19075596 Free PMC article. Review.
The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activation.
Garay JP, Karakas B, Abukhdeir AM, Cosgrove DP, Gustin JP, Higgins MJ, Konishi H, Konishi Y, Lauring J, Mohseni M, Wang GM, Jelovac D, Weeraratna A, Sherman Baust CA, Morin PJ, Toubaji A, Meeker A, De Marzo AM, Lewis G, Subhawong A, Argani P, Park BH. Garay JP, et al. Among authors: cosgrove dp. Breast Cancer Res. 2012 Feb 9;14(1):R27. doi: 10.1186/bcr3112. Breast Cancer Res. 2012. PMID: 22321971 Free PMC article.
A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours.
Wilky BA, Rudek MA, Ahmed S, Laheru DA, Cosgrove D, Donehower RC, Nelkin B, Ball D, Doyle LA, Chen H, Ye X, Bigley G, Womack C, Azad NS. Wilky BA, et al. Br J Cancer. 2015 Jan 6;112(1):24-31. doi: 10.1038/bjc.2014.515. Epub 2014 Sep 30. Br J Cancer. 2015. PMID: 25268371 Free PMC article. Clinical Trial.
Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours.
Mahalingam D, Wilding G, Denmeade S, Sarantopoulas J, Cosgrove D, Cetnar J, Azad N, Bruce J, Kurman M, Allgood VE, Carducci M. Mahalingam D, et al. Br J Cancer. 2016 Apr 26;114(9):986-94. doi: 10.1038/bjc.2016.72. Br J Cancer. 2016. PMID: 27115568 Free PMC article. Clinical Trial.
29 results